Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice (Q40237694)

18 September 2017

Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice (English)

1 reference

18 September 2017

0 references

Kumar M

1

1 reference

18 September 2017

Hunag Y

2

1 reference

18 September 2017

Glinka Y

3

1 reference

18 September 2017

Prud'homme GJ

4

1 reference

18 September 2017

Wang Q

5

1 reference

18 September 2017

31 August 2006

1 reference

18 September 2017

1 reference

18 September 2017

14

1 reference

18 September 2017

2

1 reference

18 September 2017

162-172

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302836

18 September 2017

0 references

cites work

Structure-Function of the Glucagon Receptor Family of G Protein-Coupled Receptors: The Glucagon, GIP, GLP-1, and GLP-2 Receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Formatting antibody fragments to mediate specific therapeutic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

TNFα as Therapeutic Target: New Drugs, More Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

G-protein-coupled receptor oligomerization and its potential for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

An improved plasmid DNA expression vector for direct injection into skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

21 January 2018

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Interferon gamma receptor extracellular domain expressed as IgG fusion protein in Chinese hamster ovary cells. Purification, biochemical characterization, and stoichiometry of binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Growth hormone antibodies formation in patients treated with recombinant human growth hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Immunobiology of the immature B cell: plasticity in the B-cell antigen receptor-induced response fine tunes negative selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Fc receptors and their role in immune regulation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Altering immune tolerance therapeutically: the power of negative thinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Errors of heterologous protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Laboratory animals exhibiting obesity and diabetes syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Insulin-induced drug eruptions and reliability of skin tests

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302836

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302836

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference